Typically, a promising new experimental drug arrives on the scene with a flourish. But sometimes, it’s a long and winding road.
company
OMRF collaborates with GSK to develop novel treatments for severe inflammatory diseases
This collaboration is part of GSK’s “Discovery Partnerships with Academia” (DPAc) efforts.